ProMetic Life Sciences Company Profile (TSE:PLI)

About ProMetic Life Sciences (TSE:PLI)

ProMetic Life Sciences logoPrometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs. ProMetic is also developing its own small molecule therapeutic products targeting unmet medical needs in the field of fibrosis, autoimmune disease/inflammation and cancer. It has research and development facilities in the United Kingdom, the United States and Canada; manufacturing facilities in the Isle of Man and Canada, and business development activities in the United States, Europe and Asia.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: TSE:PLI
  • CUSIP: N/A
  • Web: prometic.com/
Capitalization:
  • Market Cap: C$1.1 billion
  • Outstanding Shares: 706,041,000
Average Prices:
  • 50 Day Moving Avg: C$1.42
  • 200 Day Moving Avg: C$1.85
  • 52 Week Range: C$1.12 - C$3.24
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: C$16.33 million
  • Price / Sales: 67.45
  • Book Value: C$0.16 per share
  • Price / Book: 9.75
Profitability:
  • EBIDTA: ($119,090,000.00)
  • Net Margins: -870.60%
  • Return on Equity: -101.57%
  • Return on Assets: -50.15%
Misc:
  • Average Volume: 1.01 million shs.
  • Short Ratio: 9.83
 

Frequently Asked Questions for ProMetic Life Sciences (TSE:PLI)

What is ProMetic Life Sciences' stock symbol?

ProMetic Life Sciences trades on the Tornton Stock Exchange (TSX) under the ticker symbol "PLI."

When will ProMetic Life Sciences make its next earnings announcement?

ProMetic Life Sciences is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for ProMetic Life Sciences.

Where is ProMetic Life Sciences' stock going? Where will ProMetic Life Sciences' stock price be in 2017?

5 brokerages have issued 1 year price targets for ProMetic Life Sciences' shares. Their predictions range from C$2.50 to C$4.50. On average, they expect ProMetic Life Sciences' share price to reach C$3.60 in the next twelve months. View Analyst Ratings for ProMetic Life Sciences.

Who are some of ProMetic Life Sciences' key competitors?

Who are ProMetic Life Sciences' key executives?

ProMetic Life Sciences' management team includes the folowing people:

  • Simon Geoffrey Best, Independent Chairman of the Board
  • Pierre Laurin Ph.D., President, Chief Executive Officer, Non-Independent Director
  • Bruce Pritchard, Interim Chief Financial Officer, Chief Operating Officer
  • John Moran M.D., Chief Medical Officer, Director
  • Patrick Sartore, Chief Legal Officer and Corporate Secretary
  • Stefan Clulow, Non-Independent Director
  • Charles N. Kenworthy, Non-Independent Director
  • Bruce J. Wendel, Non-Independent Director
  • Andrew Bishop, Independent Director
  • Kenneth H. Galbraith, Independent Director

How do I buy ProMetic Life Sciences stock?

Shares of ProMetic Life Sciences and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is ProMetic Life Sciences' stock price today?

One share of ProMetic Life Sciences stock can currently be purchased for approximately C$1.56.


MarketBeat Community Rating for ProMetic Life Sciences (TSE PLI)
Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  246 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  329
MarketBeat's community ratings are surveys of what our community members think about ProMetic Life Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ProMetic Life Sciences (TSE:PLI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: C$3.60

Analysts' Ratings History for ProMetic Life Sciences (TSE:PLI)
Show:
DateFirmActionRatingPrice TargetDetails
8/30/2017National Bank FinancialBoost Price TargetC$2.00 -> C$2.50View Rating Details
8/16/2017Royal Bank Of CanadaLower Price TargetOutperformC$4.00 -> C$3.50View Rating Details
8/16/2017TD SecuritiesLower Price TargetSpeculative BuyC$4.50 -> C$3.50View Rating Details
7/7/2017ScotiabankLower Price TargetOutperformC$4.75 -> C$4.00View Rating Details
6/19/2017Canaccord GenuityLower Price TargetBuyC$4.75 -> C$4.50View Rating Details
10/13/2016Bloom BurtonReiterated RatingHoldView Rating Details
8/25/2016CIBCLower Price TargetC$5.00 -> C$4.85View Rating Details
3/28/2016Paradigm CapitalBoost Price TargetBuyC$2.90 -> C$3.30View Rating Details
1/29/2016Panmure GordonBoost Price TargetBuyC$6.70View Rating Details
(Data available from 9/24/2015 forward)

Earnings

Earnings History for ProMetic Life Sciences (TSE:PLI)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for ProMetic Life Sciences (TSE:PLI)
Current Year EPS Consensus Estimate: $-0.15 EPS

Dividends

Dividend History for ProMetic Life Sciences (TSE:PLI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ProMetic Life Sciences (TSE:PLI)
Insider Trades by Quarter for ProMetic Life Sciences (TSE:PLI)
Insider Trades by Quarter for ProMetic Life Sciences (TSE:PLI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/13/2017Pierre LaurinDirectorSell82,738C$1.44C$119,142.72
9/12/2017Pierre LaurinDirectorSell82,738C$1.45C$119,970.10
9/11/2017Bruce WendelDirectorBuy7,450C$1.21C$9,014.50
9/7/2017Pierre LaurinDirectorSell41,427C$1.45C$60,069.15
8/25/2017Bruce PritchardInsiderSell84,594C$1.15C$97,283.10
8/24/2017Dwun-Hou ChenDirectorSell32,321C$1.14C$36,845.94
8/24/2017Patrick SartoreInsiderSell64,579C$1.15C$74,265.85
8/22/2017Bruce PritchardInsiderBuy48,400C$1.30C$62,920.00
8/22/2017Simon Geoffrey BestDirectorBuy10,000C$1.29C$12,900.00
8/18/2017Louise MénardDirectorBuy6,400C$1.20C$7,680.00
8/18/2017Patrick SartoreInsiderBuy9,250C$1.21C$11,192.50
8/17/2017Nancy Orr-GaucherDirectorBuy17,200C$1.18C$20,296.00
7/10/2017Louise MénardDirectorSell82,202C$1.60C$131,523.20
6/1/2017Martin LeclercInsiderBuy7,000C$2.04C$14,280.00
5/30/2017Bruce WendelDirectorBuy2,474C$1.52C$3,760.48
5/25/2017Martin LeclercInsiderBuy8,950C$2.03C$18,168.50
5/18/2017Simon Geoffrey BestDirectorBuy10,000C$2.06C$20,600.00
4/19/2017Andrew Trevor BishopDirectorBuy10,000C$2.09C$20,900.00
4/7/2017Bruce PritchardInsiderBuy15,300C$2.18C$33,354.00
2/6/2017Bruce WendelDirectorBuy1,210C$1.66C$2,008.60
10/7/2016Simon Geoffrey BestDirectorBuy2,750C$2.93C$8,057.50
4/6/2016Bruce PritchardInsiderBuy8,800C$3.19C$28,050.88
4/5/2016Bruce WendelDirectorBuy35,200C$2.45C$86,387.84
1/21/2016Raymond Manuel HakimDirectorBuy10,000C$2.77C$27,700.00
1/20/2016Pierre LaurinDirectorBuy2,000C$2.62C$5,240.00
1/19/2016Gregory WeaverInsiderBuy25,000C$2.78C$69,500.00
1/12/2016Louise M�NardDirectorBuy1,867C$2.94C$5,488.98
12/31/2015Kurt Stefan Victor ClulowDirectorBuy273,800C$3.42C$937,737.62
12/29/2015Kurt Stefan Victor ClulowDirectorBuy232,700C$3.22C$749,875.75
12/21/2015Kurt Stefan Victor ClulowDirectorBuy439,500C$3.16C$1,388,160.75
12/4/2015Gregory WeaverInsiderBuy5,000C$2.14C$10,706.50
12/3/2015Gregory WeaverInsiderBuy5,000C$2.24C$11,184.00
12/3/2015Pierre LaurinDirectorSell259,125C$2.99C$774,913.31
11/17/2015Jonathan BoothInsiderBuy25,000C$2.21C$55,225.00
9/30/2015Kurt Stefan Victor ClulowDirectorBuy50,000C$1.43C$71,500.00
9/29/2015Kurt Stefan Victor ClulowDirectorBuy153,400C$1.42C$217,889.36
9/25/2015Raymond Manuel HakimDirectorBuy15,000C$1.69C$25,399.50
9/15/2015Andrew Trevor BishopDirectorBuy10,000C$1.81C$18,100.00
9/8/2015Simon Geoffrey BestDirectorBuy30,000C$1.95C$58,464.00
8/24/2015Nancy Orr-GaucherDirectorBuy2,800C$1.75C$4,900.00
8/21/2015Pierre LaurinDirectorBuy2,400C$1.83C$4,392.00
7/16/2015Simon Geoffrey BestDirectorBuy60,000C$2.43C$145,782.00
7/15/2015Patrick SartoreInsiderSell122,736C$2.30C$282,722.38
7/15/2015Steven J BurtonDirectorSell49,842C$2.30C$114,811.05
7/2/2015Kurt Stefan Victor ClulowDirectorBuy229,900C$2.32C$533,184.08
6/30/2015Kurt Stefan Victor ClulowDirectorBuy770,100C$2.26C$1,742,736.30
6/29/2015Kurt Stefan Victor ClulowDirectorBuy114,750C$2.10C$240,435.68
6/26/2015Kurt Stefan Victor ClulowDirectorBuy885,250C$2.12C$1,879,208.70
6/16/2015Patrick SartoreInsiderBuy2,300C$2.24C$5,152.00
6/12/2015Patrick SartoreInsiderBuy4,000C$2.28C$9,122.00
6/11/2015Louise M�NardDirectorBuy10,000C$2.35C$23,500.00
6/5/2015Raymond Manuel HakimDirectorBuy50,000C$2.45C$122,495.00
6/4/2015Paul MesburisDirectorSell115,593C$2.40C$277,423.20
5/22/2015Nancy Orr-GaucherDirectorSell9,787C$2.47C$24,173.89
4/9/2015Nancy Orr-GaucherDirectorSell9,657C$2.72C$26,267.04
4/7/2015Bruce PritchardInsiderBuy10,200C$2.74C$27,943.92
2/6/2015John Edward MoranDirectorBuy64,500C$1.51C$97,395.00
1/12/2015Patrick SartoreInsiderSell279,656C$1.87C$523,348.24
1/12/2015Pierre LaurinDirectorSell956,264C$1.87C$1,789,552.45
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ProMetic Life Sciences (TSE:PLI)
Latest Headlines for ProMetic Life Sciences (TSE:PLI)
Source:
DateHeadline
finance.yahoo.com logoProMetic Life Sciences, Inc. – Value Analysis (TORONTO:PLI) : September 22, 2017
finance.yahoo.com - September 22 at 1:18 PM
reuters.com logoBRIEF-Prometic reports positive clinical data from ongoing PBI-4050 study in Alström Syndrome patients
www.reuters.com - September 20 at 7:47 AM
prnewswire.com logoPrometic Reports Positive Clinical Data from Ongoing PBI-4050 Study in Alström Syndrome Patients - PR Newswire (press release)
www.prnewswire.com - September 19 at 6:34 AM
prnewswire.com logoPrometic Reports Positive Clinical Data from Ongoing PBI-4050 Study in Alström Syndrome Patients - PR Newswire (press release)
www.prnewswire.com - September 19 at 6:34 AM
finance.yahoo.com logoPrometic Reports Positive Clinical Data from Ongoing PBI-4050 Study in Alström Syndrome Patients
finance.yahoo.com - September 19 at 6:34 AM
finance.yahoo.com logoPrometic Reports Positive Clinical Data from Ongoing PBI-4050 Study in Alström Syndrome Patients
finance.yahoo.com - September 19 at 6:34 AM
americanbankingnews.com logoPierre Laurin Sells 82,738 Shares of ProMetic Life Sciences Inc. (PLI) Stock
www.americanbankingnews.com - September 15 at 4:32 PM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Director Pierre Laurin Sells 82,738 Shares
www.americanbankingnews.com - September 15 at 4:32 PM
americanbankingnews.com logoInsider Selling: ProMetic Life Sciences Inc. (PLI) Director Sells 41,427 Shares of Stock
www.americanbankingnews.com - September 12 at 10:16 PM
finance.yahoo.com logoProMetic Life Sciences, Inc. breached its 50 day moving average in a Bullish Manner : PLI-CA : August 31, 2017
finance.yahoo.com - September 1 at 7:20 AM
americanbankingnews.com logoBruce Pritchard Sells 84,594 Shares of ProMetic Life Sciences Inc. (PLI) Stock
www.americanbankingnews.com - August 31 at 4:08 AM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 30 at 2:32 PM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Price Target Raised to C$2.50 at National Bank Financial
www.americanbankingnews.com - August 30 at 1:50 PM
baystreet.ca logoPrometic Stock Pops on FDA Designation
www.baystreet.ca - August 30 at 8:03 AM
fool.ca logoProMetic Life Sciences Inc. Jumps More Than 21% on FDA Designation
www.fool.ca - August 30 at 8:03 AM
finance.yahoo.com logoETFs with exposure to ProMetic Life Sciences, Inc. : August 30, 2017
finance.yahoo.com - August 30 at 8:03 AM
americanbankingnews.com logoPatrick Sartore Sells 64,579 Shares of ProMetic Life Sciences Inc. (PLI) Stock
www.americanbankingnews.com - August 29 at 10:34 PM
americanbankingnews.com logoDwun-Hou Chen Sells 32,321 Shares of ProMetic Life Sciences Inc. (PLI) Stock
www.americanbankingnews.com - August 25 at 8:52 PM
seekingalpha.com logoThe Pharma Race: A New Treatment For Idiopathic Pulmonary Fibrosis
seekingalpha.com - August 22 at 3:25 PM
finance.yahoo.com logoProMetic Life Sciences, Inc. :PLI-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 22, 2017
finance.yahoo.com - August 22 at 3:25 PM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Insider Patrick Sartore Buys 9,250 Shares
www.americanbankingnews.com - August 22 at 1:32 PM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Director Acquires C$12,900.00 in Stock
www.americanbankingnews.com - August 22 at 1:32 PM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Insider Bruce Pritchard Purchases 48,400 Shares
www.americanbankingnews.com - August 22 at 1:32 PM
americanbankingnews.com logoProMetic Life Sciences Inc. Expected to Earn FY2017 Earnings of ($0.14) Per Share (PLI)
www.americanbankingnews.com - August 18 at 7:32 AM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Director Nancy Orr-Gaucher Purchases 17,200 Shares
www.americanbankingnews.com - August 17 at 4:58 PM
finance.yahoo.com logoETFs with exposure to ProMetic Life Sciences, Inc. : August 16, 2017
finance.yahoo.com - August 17 at 6:54 AM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) PT Lowered to C$3.50
www.americanbankingnews.com - August 16 at 2:41 PM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Price Target Lowered to C$3.50 at TD Securities
www.americanbankingnews.com - August 16 at 2:38 PM
finance.yahoo.com logoEdited Transcript of PLI.TO earnings conference call or presentation 15-Aug-17 3:00pm GMT
finance.yahoo.com - August 16 at 6:47 AM
americanbankingnews.com logoProMetic Life Sciences Inc. (TSE:PLI) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - August 9 at 11:48 AM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 5 at 5:02 PM
finance.yahoo.com logoProMetic Life Sciences, Inc. :PLI-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017
finance.yahoo.com - August 4 at 7:02 AM
prnewswire.com logoPrometic Announces Positive Long Term Clinical Data on Ryplazym™ in Plasminogen Congenital Deficiency and ... - PR Newswire (press release)
www.prnewswire.com - July 13 at 8:01 AM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Director Sells C$131,523.20 in Stock
www.americanbankingnews.com - July 11 at 5:30 PM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - July 11 at 5:30 PM
americanbankingnews.com logoScotiabank Cuts ProMetic Life Sciences Inc. (PLI) Price Target to C$4.00
www.americanbankingnews.com - July 7 at 2:06 PM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Price Target Lowered to C$4.50 at Canaccord Genuity
www.americanbankingnews.com - June 19 at 10:23 AM
reuters.com logoBRIEF-Prometic reports $53 mln bought deal offering
www.reuters.com - June 16 at 8:58 AM
prnewswire.com logoNew data presented by Prometic at ADA's Scientific Sessions validates PBI-4050's positive impact on kidneys in ... - PR Newswire (press release)
www.prnewswire.com - June 12 at 7:50 AM
finance.yahoo.com logoNew data presented by Prometic at ADA's Scientific Sessions validates PBI-4050's positive impact on kidneys in patients with diabetes and metabolic syndrome
finance.yahoo.com - June 12 at 7:50 AM
americanbankingnews.com logoInsider Buying: ProMetic Life Sciences Inc. (PLI) Insider Buys 7,000 Shares of Stock
www.americanbankingnews.com - June 1 at 4:50 PM
americanbankingnews.com logoMartin Leclerc Buys 8,950 Shares of ProMetic Life Sciences Inc. (PLI) Stock
www.americanbankingnews.com - May 26 at 10:35 AM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Earns "Outperform" Rating from Royal Bank of Canada
www.americanbankingnews.com - May 24 at 10:59 AM
prnewswire.com logoPrometic Presents New Data on PBI-4050 and Plasminogen at the American Thoracic Society's 2017 - PR Newswire (press release)
www.prnewswire.com - May 24 at 10:04 AM
reuters.com logoBRIEF-Prometic presents new data on PBI-4050 and plasminogen
www.reuters.com - May 23 at 9:52 AM
finance.yahoo.com logoPrometic Presents New Data on PBI-4050 and Plasminogen at the American Thoracic Society's 2017 International Conference
finance.yahoo.com - May 23 at 9:52 AM
americanbankingnews.com logoSimon Geoffrey Best Buys 10,000 Shares of ProMetic Life Sciences Inc. (PLI) Stock
www.americanbankingnews.com - May 19 at 4:24 PM
americanbankingnews.com logoProMetic Life Sciences Inc. (PLI) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 19 at 10:07 AM
americanbankingnews.com logoNational Bank Financial Weighs in on ProMetic Life Sciences Inc.'s FY2017 Earnings (PLI)
www.americanbankingnews.com - May 19 at 8:04 AM
finance.yahoo.com logoPrometic Reports 2017 First Quarter Highlights and Financial Results
finance.yahoo.com - May 16 at 9:50 AM

Social

Chart

ProMetic Life Sciences (PLI) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff